Display options
Cite
Kummer M, El-Battrawy I, Gietzen T, et al. The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. Front Pharmacol. 2020;11:681doi: 10.3389/fphar.2020.00681.
Kummer, M., El-Battrawy, I., Gietzen, T., Ansari, U., Behnes, M., Lang, S., Zhou, X., Borggrefe, M., & Akin, I. (2020). The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. Frontiers in pharmacology, 11681. https://doi.org/10.3389/fphar.2020.00681
Kummer, Marvin, et al. "The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome." Frontiers in pharmacology vol. 11 (2020): 681. doi: https://doi.org/10.3389/fphar.2020.00681
Kummer M, El-Battrawy I, Gietzen T, Ansari U, Behnes M, Lang S, Zhou X, Borggrefe M, Akin I. The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome. Front Pharmacol. 2020 May 14;11:681. doi: 10.3389/fphar.2020.00681. eCollection 2020. PMID: 32477140; PMCID: PMC7240099.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2020 May 14;11:681. doi: 10.3389/fphar.2020.00681. eCollection 2020.

The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome.

Frontiers in pharmacology

Marvin Kummer, Ibrahim El-Battrawy, Thorsten Gietzen, Uzair Ansari, Michael Behnes, Siegfried Lang, Xiaobo Zhou, Martin Borggrefe, Ibrahim Akin

Affiliations

  1. First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany.
  2. DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.

PMID: 32477140 PMCID: PMC7240099 DOI: 10.3389/fphar.2020.00681

Abstract

BACKGROUND: Takotsubo syndrome (TTS) and acute coronary syndrome (ACS) patients have a similar mortality rate. In this study, we sought to determine the short- and long-term outcome of TTS patients as compared to ACS patients both treated with beta-blockers.

OBJECTIVES: In the present study we described the data of 5 years of follow up of 103 TTS and 422 ACS patients both treated with beta-blockers.

METHODS: Data from TTS patients were included retrospectively and prospectively, ACS patients were included retrospectively. All retrospectively included patients have been followed up for 5 years. The end point in this study was the occurrence of death.

RESULTS: TTS affected significantly more women (87.4%) than ACS (34.6%) (p < 0.01). TTS patients suffered significantly more often from thromboembolic events (14.6% versus 2.1%; p < 0.01) and cardiogenic shock (11.9% versus 3.6%; p < 0.01) than the ACS group. TTS patients had a significantly higher long-term mortality (within 5 years) as compared to ACS patients (17.5% versus 3.6%) (p < 0.01). Patients of the TTS group compared to the ACS group did not benefit from combination of beta-blockers and ACE-inhibitors in terms of long-term mortality (p < 0.01). As we compare TTS patients who were treated with beta-blockers and ACE-inhibitors versus single use of beta-blockers there was no difference in long-term mortality (p = 0.918).

CONCLUSION: TTS patients had a significantly higher long-term mortality (within 5 years) than patients with an ACS.

Copyright © 2020 Kummer, El-Battrawy, Gietzen, Ansari, Behnes, Lang, Zhou, Borggrefe and Akin.

Keywords: Takotsubo syndrome (TTS); ace-inhibitors; acute coronary syndrome; beta-blockers; long-term mortality

References

  1. Eur Heart J Acute Cardiovasc Care. 2016 Oct;5(6):489-496 - PubMed
  2. Int J Cardiol. 2018 Mar 1;254:195-202 - PubMed
  3. Clin Cardiol. 2014 Jul;37(7):434-9 - PubMed
  4. Expert Rev Cardiovasc Ther. 2019 Feb;17(2):83-93 - PubMed
  5. Eur J Heart Fail. 2016 Jan;18(1):8-27 - PubMed
  6. Eur Heart J. 2016 Jan 14;37(3):267-315 - PubMed
  7. Int J Cardiol. 2017 Apr 15;233:97 - PubMed
  8. Int J Cardiol. 2018 Sep 15;267:22-27 - PubMed
  9. Eur J Clin Invest. 2017 Jul;47(7):477-485 - PubMed
  10. J Investig Med. 2015 Oct;63(7):844-55 - PubMed
  11. J Clin Hypertens (Greenwich). 2005 Jul;7(7):409-16 - PubMed
  12. Circ J. 2019 Jan 25;83(2):281-282 - PubMed
  13. J Am Heart Assoc. 2018 Oct 2;7(19):e010004 - PubMed
  14. Heart. 2016 Jul 1;102(13):1029-35 - PubMed
  15. Europace. 2017 Aug 1;19(8):1288-1292 - PubMed
  16. World J Cardiol. 2014 Jul 26;6(7):602-9 - PubMed
  17. Int J Cardiol. 2015 Apr 15;185:282-9 - PubMed
  18. J Am Coll Cardiol. 2018 Jan 23;71(3):368 - PubMed
  19. N Engl J Med. 2015 Sep 3;373(10):929-38 - PubMed
  20. Europace. 2018 May 1;20(5):843-850 - PubMed
  21. Cureus. 2020 Jan 3;12(1):e6556 - PubMed
  22. Eur J Heart Fail. 2019 Jun;21(6):781-789 - PubMed
  23. Eur Heart J. 2011 Dec;32(23):2999-3054 - PubMed

Publication Types